Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade.
Sapna YadavilliJeremy D WaightSara BrettMeixia BiTianqian ZhangYao-Bin LiuCatherine EllisDavid C TurnerAshleigh HahnHong ShiLaura Seestaller-WehrJunping JingQing XieJafar Sadik ShaikXiao JiRobert GagnonWilliam FielesLaura HookSteven GrantStephanie HopleyM Phillip DeYoungChristina BlackwellMichael ChisamoreRobert BiddlecombeDavid J FigueroaChristopher B HopsonRoopa SrinivasanJames SmothersMichele MaioDanny RischinDaniel OliveElaine PaulPatrick A MayesAxel HoosMarc BallasPublished in: Cancer research communications (2023)
Stimulation of the T-cell activation marker ICOS with the anti-ICOS agonist mAb feladilimab, alone and in combination with PD-1 inhibition, induces antitumor activity across nonclinical models as well as select patients with advanced solid tumors.